Context Therapeutics (CNTX)
0.59
-0.02 (3.28%)
Upcoming Events
Latest Headlines
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026 4:05 PM - StreetInsider
Context Therapeutics added to Russell 2000 and Russell 3000 indexes
July 6, 2026 4:07 PM - StreetInsider
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
July 6, 2026 4:07 PM - Globe NewsWire
Form 4 Context Therapeutics For: Jun 24 Filed by: Pasternak Andy
June 26, 2026 4:24 PM - SEC Filing
Form 4 Context Therapeutics For: Jun 24 Filed by: Stacey Jennifer Evans
June 26, 2026 4:22 PM - SEC Filing
Form 4 Context Therapeutics For: Jun 24 Filed by: West Linda
June 26, 2026 4:21 PM - SEC Filing
Form 4 Context Therapeutics For: Jun 24 Filed by: Smith Karen L.
June 26, 2026 4:21 PM - SEC Filing
Form 4 Context Therapeutics For: Jun 24 Filed by: Walker Luke Nathaniel
June 26, 2026 4:20 PM - SEC Filing
Form 4 Context Therapeutics For: Jun 24 Filed by: Kantoff Philip W.
June 26, 2026 4:14 PM - SEC Filing
Form 8-K Context Therapeutics For: Jun 24
June 26, 2026 4:08 PM - SEC Filing
Context Therapeutics (CNTX) PT Lowered to $4 at Maxim Group
June 16, 2026 9:55 AM - StreetInsider
Form 8-K Context Therapeutics For: Jun 15
June 15, 2026 9:19 AM - SEC Filing
Context Therapeutics reports interim phase 1 trial results for CTIM-76
June 15, 2026 6:30 AM - StreetInsider
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
June 15, 2026 6:30 AM - StreetInsider
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 9, 2026 4:10 PM - Globe NewsWire
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
May 27, 2026 7:30 AM - StreetInsider
Form 8-K Context Therapeutics For: May 14
May 18, 2026 6:47 AM - SEC Filing
Context Therapeutics amends BioAtla license deal for CT-202 drug
May 18, 2026 6:45 AM - StreetInsider
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026 6:45 AM - Globe NewsWire
Form SCHEDULE 13G/A Context Therapeutics Filed by: GREAT POINT PARTNERS LLC
May 15, 2026 8:55 AM - SEC Filing
Form SCHEDULE 13G/A Context Therapeutics Filed by: Blue Owl Capital Holdings LP
May 14, 2026 4:21 PM - SEC Filing
Form SCHEDULE 13G Context Therapeutics Filed by: Octagon Capital Advisors LP
May 14, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G/A Context Therapeutics Filed by: Avidity Partners Management LP
May 12, 2026 3:08 PM - SEC Filing
Form SCHEDULE 13G/A Context Therapeutics Filed by: Soleus Capital Master Fund, L.P.
May 8, 2026 5:01 PM - SEC Filing
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
May 6, 2026 4:18 PM - Globe NewsWire
Form 10-Q Context Therapeutics For: Mar 31
May 6, 2026 4:11 PM - SEC Filing
Form 8-K Context Therapeutics For: Apr 30
May 1, 2026 4:08 PM - SEC Filing
Form ARS Context Therapeutics For: Dec 31
April 28, 2026 4:30 PM - SEC Filing
Form DEFA14A Context Therapeutics
April 28, 2026 4:17 PM - SEC Filing
Form DEF 14A Context Therapeutics For: Apr 28
April 28, 2026 4:13 PM - SEC Filing
Full Article List
